PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
289 / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.76%
Negative revenue growth while ECL.AX stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
1.59%
Gross profit growth of 1.59% while ECL.AX is zero. Bruce Berkowitz would see if minimal improvements could expand further.
59.24%
EBIT growth of 59.24% while ECL.AX is zero. Bruce Berkowitz would see if small gains can be scaled further.
59.24%
Operating income growth of 59.24% while ECL.AX is zero. Bruce Berkowitz would see if this modest edge can become significant.
-96.52%
Negative net income growth while ECL.AX stands at 0.00%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.93%
Share count expansion well above ECL.AX's 0.00%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
1.93%
Diluted share change of 1.93% while ECL.AX is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
97.84%
OCF growth of 97.84% while ECL.AX is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
69.41%
FCF growth of 69.41% while ECL.AX is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
-90.53%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-56.69%
Negative 5Y CAGR while ECL.AX stands at 18.81%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-57.18%
Negative 3Y CAGR while ECL.AX stands at 39.83%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-100.04%
Negative 10Y OCF/share CAGR while ECL.AX stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
99.83%
Positive OCF/share growth while ECL.AX is negative. John Neff might see a comparative advantage in operational cash viability.
-100.40%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-99.95%
Negative 10Y net income/share CAGR while ECL.AX is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
100.07%
5Y net income/share CAGR at 50-75% of ECL.AX's 157.28%. Martin Whitman might see a shortfall in operational efficiency or brand power.
100.31%
Below 50% of ECL.AX's 3021.22%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.30%
R&D growth of 6.30% while ECL.AX is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
-15.35%
We cut SG&A while ECL.AX invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.